Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the grant of equity inducement awards to seven new non-executive employees on July 1, 2026. These awards, consisting of options to purchase 604 shares and 2,952 time-based restricted stock units, were approved by the independent Compensation Committee as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants are subject to specific vesting schedules and the employees' continued employment.
Madrigal gives seven new employees stock awards to join the company
Madrigal Pharmaceuticals granted equity inducement awards to seven new non-executive employees on July 1, 2026. These awards include 604 stock options and 2,952 time-based Restricted Stock Units (RSUs), with an exercise price of $514.39 per share, as part of the company's 2025 Inducement Plan. The awards are subject to multi-year vesting schedules tied to continued employment, aiming to attract and retain talent.
Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative
Madrigal Pharmaceuticals' investment narrative is largely centered on its drug Rezdiffra for MASH. The recent progression of its siRNA partnership with Suzhou Ribo Life Science into IND-enabling studies introduces a new RNA-based approach to its pipeline, diversifying its development efforts for liver disease. While this siRNA candidate offers future potential, the company’s immediate focus and primary investment driver remain the clinical and commercial success of Rezdiffra.
MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales, earnings per share, and stock performance over different periods.
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL
The article displays the enterprise value to EBITDA forward for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). The content comes from TradingView, referencing financial data from ICE Data Services and FactSet, and SEC filings from Quartr.
Madrigal and Ribo start IND-enabling studies after MASH milestone
Madrigal Pharmaceuticals and Suzhou Ribo Life Science have achieved a significant milestone in their siRNA partnership for liver disease, nominating a candidate drug for MASH (Metabolic Dysfunction-Associated Steatohepatitis). This triggers the immediate start of IND-enabling studies, moving the program closer to clinical trials. The collaboration leverages Madrigal's clinical expertise in MASH and Ribo's siRNA discovery capabilities to develop novel RNA therapeutics for a high unmet medical need.
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Suzhou Ribo Life Science Co., Ltd. (Ribo) and Madrigal Pharmaceuticals, Inc. (Madrigal) have achieved their first major milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH) therapies. This success involves the nomination of a candidate drug, leading to the immediate initiation of IND-enabling studies. The collaboration leverages Ribo's siRNA drug discovery and delivery expertise and Madrigal's clinical presence in MASH, aiming to accelerate novel therapeutic options for patients globally.
Medicare Coverage Could Put These Obesity Drug Stocks In Focus
A Supreme Court ruling and Medicare's decision to cover obesity drugs have brought the obesity and metabolic drug space into focus. This article highlights three companies—Madrigal Pharmaceuticals (MDGL), Rhythm Pharmaceuticals (RYTM), and Protagonist Therapeutics (PTGX)—that are particularly exposed to these developments. Each company has unique strengths and risks related to its drug pipeline, market positioning, and financial health, making them potential points of interest for investors.
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL
The article focuses on the enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc., traded on NASDAQ under the symbol MDGL. It appears to be a financial data page from TradingView, providing an overview of the company's financials without offering detailed analytical text in this snippet. The content primarily lists navigation and site-specific information rather than direct financial analysis.
Madrigal Pharmaceuticals, Inc.(NasdaqGS: MDGL) added to Russell 1000 Dynamic Index
Madrigal Pharmaceuticals, Inc. (NasdaqGS: MDGL) has been added to the Russell 1000 Dynamic Index. This news was published on June 28, 2026. The company is focused on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and its medication, Rezdiffra, is approved by the FDA for MASH treatment.
Price to earnings forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL
This article provides a brief overview of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) financials, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of the article. The content is primarily a gateway to financial data and tools rather than an in-depth analysis.
Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell 1000 Growth Benchmark
Madrigal Pharmaceuticals (MDGL) has been added to the Russell 1000 Growth Benchmark. The biopharmaceutical company focuses on therapeutics for MASH, with its drug Rezdiffra being the only FDA-approved medication for MASH with moderate to advanced fibrosis, and an ongoing trial for MASH cirrhosis. The article also provides recent news and financial details for the company.
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL
This article provides financial information for Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), specifically detailing its enterprise value to EBIT forward. It indicates a period value, along with changes and percentage changes, derived from data providers like ICE Data Services and FactSet.
Price to sales forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1
This article provides the "Price to sales forward" value for Madrigal Pharmaceuticals, Inc. (SWB:YDO1) on the Stuttgart Stock Exchange. The specific value and any changes are indicated, along with a note that the information was "Made by humans."
(MDGL) Volatility Zones as Tactical Triggers
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) shows strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, incorporating sophisticated risk management. The article highlights an exceptional 50.7:1 risk-reward short setup, targeting 14.6% downside versus 0.3% risk.
MDGL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Madrigal Pharmaceuticals (MDGL) stock through 2027, including current analyst price targets and ratings. It also offers key financial data such as current stock price, market capitalization, historical highs and lows, and upcoming earnings report dates. The content addresses frequently asked questions about MDGL's stock performance and financial metrics.
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900
Piper Sandler has reiterated its Buy rating for Madrigal Pharmaceuticals (MDGL.US) and maintained its target price of $900. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900
Piper Sandler has reiterated an Overweight rating and a $900 price target for Madrigal Pharmaceuticals (NASDAQ:MDGL), citing increased confidence in the management's execution of REZDIFFRA's launch and pipeline expansion following an investor dinner. The firm believes Madrigal Pharmaceuticals is positioning itself as a biopharmaceutical leader in the MASH market, with REZDIFFRA expected to be a multi-blockbuster opportunity. This positive outlook is supported by strong revenue growth and expectations for Phase 3 data in 2027 that could lead to full approval for REZDIFFRA in F2-F4 MASH.
Is Madrigal Pharmaceuticals’ (MDGL) Expanded Shelf and Inducement Plan Reframing Its Equity Strategy Narrative?
Madrigal Pharmaceuticals (MDGL) recently filed a US$717.70 million shelf registration for common shares and granted restricted stock units to new employees, highlighting their continued use of stock-based funding. This move reinforces that future dilution and financing are key considerations for investors, alongside execution risks for their drug Rezdiffra. While the shelf registration provides potential funding, it underscores the need for investors to weigh how bullish assumptions might evolve with new financing and pricing data.
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A Biotech Gem with a 34% Upside Potential
Madrigal Pharmaceuticals (MDGL) is highlighted as an intriguing investment opportunity in the biotechnology sector, primarily due to its focus on metabolic dysfunction-associated steatohepatitis (MASH) and its advancing product, Rezdiffra. Analysts project a potential upside of 34.20% with an average target price of $678.71, supported by 11 out of 13 analysts issuing "buy" ratings. Despite negative EPS and free cash flow, common in early-stage biotech, the company's strong revenue growth and focus on a high-demand therapeutic area suggest promising long-term potential for patient investors.
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals announced the granting of inducement awards in compliance with Nasdaq Listing Rule 5635(C)(4). The brief news item, sourced from Reuters via Refinitiv, did not provide further details regarding the nature or recipients of these awards.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the grant of equity inducement awards to five new non-executive employees on June 15, 2026, under its 2025 Inducement Plan. These awards, consisting of 1,397 time-based restricted stock units, were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize new hires. The restricted stock units will vest in four equal annual installments, contingent upon continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced that it granted equity inducement awards to five new non-executive employees on June 15, 2026. These awards, totaling 1,397 time-based restricted stock units, were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for their employment, with vesting occurring in four equal annual installments contingent on continued employment.
MDGL - EU Expansion and Combination Therapies Will Drive Future Opportunity
Madrigal Pharmaceuticals (MDGL) is poised for future growth driven by the EU expansion of its MASH drug, Rezdiffra, and the development of combination therapies. Analyst consensus indicates a fair value of $678.71, suggesting the stock is currently undervalued, despite some bearish concerns about sustaining the initial launch pace and competition. The company's patent protection for Rezdiffra extending to 2045 and upcoming international launches, alongside strong cash reserves, are seen as key catalysts for long-term revenue growth and market penetration.
Madrigal (MDGL) director James Daly granted RSUs and 766-share option
Madrigal Pharmaceuticals director James M. Daly was granted 454 restricted stock units and a stock option for 766 shares with an exercise price of $499.86 per share. Both awards vest 100% on the earlier of June 17, 2027, or the date of Madrigal’s 2027 annual meeting of stockholders, contingent on Daly's continued service. Following these grants, Daly directly holds 3,081 shares of common stock and the new option.
Madrigal Pharmaceuticals Inc
This article provides an overview of Madrigal Pharmaceuticals Inc (MDGL), including its stock price, market capitalization, and a note that its revenue breakdown by business segments and regions has not been disclosed. It is primarily a placeholder or incomplete financial data page from TradingKey. The company's stock was trading at $505.750, up 1.18% at the close on June 18th.
Madrigal Shareholders Approve 2026 Equity Compensation Plans
Madrigal Pharmaceuticals shareholders approved new 2026 Stock and Employee Stock Purchase Plans, re-elected directors, endorsed executive pay, and ratified their auditor. The company also adopted a Nonqualified Deferred Compensation Plan for executives and directors and transitioned Dr. Rebecca Taub to a consulting role. An analyst has a "Hold" rating on MDGL stock with a $542.00 price target.
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes
Madrigal Pharmaceuticals shareholders have approved new equity plans, including a 2026 Stock Plan, a 2026 Employee Stock Purchase Plan, and a Nonqualified Deferred Compensation Plan, to incentivize employees and directors. Additionally, shareholders re-elected three Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent accounting firm. These decisions follow a recent earnings surprise for Q1 2026 and come amidst mixed analyst sentiment regarding their drug Rezdiffra.
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity
Madrigal Pharmaceuticals director Rebecca Taub reported new equity awards, including 454 restricted stock units and a stock option for 766 shares at an exercise price of $499.86, both vesting on the earlier of June 17, 2027, or the company's 2027 annual meeting. Following these transactions, she directly holds 452,667 shares and indirectly holds 655,540 shares through SQN LLC. The filing provides details on the insider trading activity and the associated SEC Form 4.
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants
Madrigal Pharmaceuticals director Richard S. Levy was granted 454 restricted stock units and 766 stock options with an exercise price of $499.86 per share. Both equity awards will vest on the earlier of June 17, 2027, or the company's 2027 annual stockholder meeting, provided Levy remains in service. Following these grants, Richard Levy directly holds 22,469 common shares of Madrigal Pharmaceuticals.
Madrigal (MDGL) director receives stock grants and 681-share option award
Madrigal Pharmaceuticals director Daniel J. Brennan was awarded 404 shares of common stock as restricted stock units and a stock option for 681 shares with an exercise price of $499.86. Both awards are equity compensation that vest fully on the earlier of June 17, 2027, or the company’s 2027 annual stockholder meeting, provided he remains in service. Following these grants, Brennan holds 1,371 common shares and 681 option shares directly.
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com
Madrigal Pharmaceuticals shareholders recently approved new equity plans, board changes, and a nonqualified deferred compensation plan. The company, which has seen a 79% return over the past year, also re-elected three Class I directors and ratified its independent accounting firm. These developments, along with strong Q1 2026 earnings and upcoming clinical data presentations, have led to mixed analyst outlooks on the company's future performance.
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans
Madrigal Pharmaceuticals announced updates to its compensation plans, with shareholders approving a new 2026 Stock Plan and a 2026 Employee Stock Purchase Plan. The board also adopted a Nonqualified Deferred Compensation Plan, effective August 1, 2026, allowing executives and directors to defer compensation into notional investments. Additionally, Dr. Rebecca Taub will transition to a consulting role, providing scientific and medical guidance for MASH programs for an annual fee of $100,000.
Price-Driven Insight from (MDGL) for Rule-Based Strategy
This article provides a price-driven insight for Madrigal Pharmaceuticals Inc. (MDGL) based on AI models, highlighting a mid-channel oscillation pattern and an exceptional risk-reward setup. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with a multi-timeframe signal analysis. The analysis suggests positive near-term sentiment that may overcome a weak mid-term bias within a long-term strength context.
3 Under-the-Radar Stocks to Buy and Hold for a Decade
This article identifies three innovative biotech companies—Madrigal Pharmaceuticals, Axsome Therapeutics, and Kailera Therapeutics—with strong long-term growth potential. Madrigal Pharmaceuticals leads in MASH treatment, Axsome Therapeutics has expanding approved drugs for depression and Alzheimer's agitation, and Kailera Therapeutics is a promising, albeit riskier, entrant in the rapidly growing weight-loss market. The author suggests these companies could offer excellent returns over the next decade due to their focus on high unmet medical needs and promising pipelines.
Does New Rezdiffra MASH Data Shift the Bull Case for Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals is preparing to present new clinical and real-world data for its MASH drug, Rezdiffra, at the EASL Congress 2026, which is expected to significantly influence its investment narrative. While the company projects substantial revenue and earnings, the commercial trajectory of Rezdiffra faces mixed analyst reactions due to competition and payer scrutiny. The upcoming data could clarify the drug's efficacy and safety, especially for harder-to-treat patients, and shape perceptions of its long-term viability and differentiation in the market.
Madrigal Pharmaceuticals (MDGL) Stock Valuation As Rezdiffra Data Plans And Mixed Analyst Updates Shape Expectations
Madrigal Pharmaceuticals (MDGL) is under investor scrutiny due to analyst commentary on its MASH treatment, Rezdiffra, and plans to release new clinical data at the EASL Congress 2026, alongside a presentation at the Goldman Sachs 47th Annual Global Healthcare Conference. Despite recent share price declines, long-term returns remain strong, with current analyst targets suggesting the stock is undervalued at $671.07. The company's future performance hinges on Rezdiffra's success and competitive landscape.
Madrigal Pharmaceuticals (MDGL) Stock Valuation As Rezdiffra Data Plans And Mixed Analyst Updates Shape Expectations
Madrigal Pharmaceuticals (MDGL) is under investor scrutiny following mixed analyst commentary on its MASH treatment, Rezdiffra, and upcoming data presentations. Despite recent stock dips, the company's valuation narrative suggests it is 28.4% undervalued, with a fair value target of $671.07 per share. The article advises investors to assess the numbers themselves, considering the split sentiment and potential opportunities in other healthcare AI stocks.
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound?
Madrigal Pharmaceuticals (MDGL) has seen its stock price drop by 7.9% since its last earnings report, underperforming the S&P 500's growth of 1.1%. The article questions whether the company can rebound from this recent decline. Investors will be watching for future reports and market reactions to assess its recovery potential.
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly
Madrigal Pharmaceuticals has launched "MASH Across America," an initiative featuring a 20-foot-tall inflatable liver, to raise awareness about fatty liver disease and its advanced form, MASH. The campaign debuted in Philadelphia's Fairmount Park, educating the public on liver health and the progression of liver diseases. The Giant Inflatable Liver will tour various cities nationwide to highlight the critical functions of the liver and the urgent need for public education on this underdiagnosed health crisis.
BofA cuts Madrigal Pharmaceuticals price target on competition concerns
BofA Securities has lowered its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) from $550 to $542, while maintaining a Neutral rating, due to growing concerns over competition for its drug, Rezdiffra, in the MASH market. Despite the reduction, the stock currently trades below InvestingPro's Fair Value. The firm's analysis, including discussions with key opinion leaders, suggests potential long-term challenges for Rezdiffra's market positioning, although near-term headwinds are seen as limited.
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com
BofA Securities has lowered its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $542 from $550, while maintaining a Neutral rating, due to concerns about competition and the sustainability of Rezdiffra's launch pace in MASH. Despite the target cut, the stock trades below InvestingPro’s Fair Value, suggesting it might be undervalued. This revision comes amidst Madrigal's stock being down 19% year-to-date, contrasting with its 60% gain over the past year, although recent positive earnings and analyst upgrades from other firms highlight ongoing mixed sentiment.
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound?
This article discusses Madrigal Pharmaceuticals (MDGL) stock performance, noting a 7.9% decrease since its last earnings report. It raises the question of whether the stock can rebound from this decline. The content prompts investors to consider factors that might influence its future trajectory.
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL
Goldman Sachs Group Inc. reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 20.8% in the fourth quarter of 2025, selling over 80,000 shares. Despite this trim, the biopharmaceutical company reported stronger-than-expected quarterly results and holds a "Moderate Buy" consensus rating from analysts. However, recent insider selling activity has also been noted.
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Fiera Capital Corp increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 32.6% in the fourth quarter, purchasing an additional 41,656 shares, bringing its total to 169,456 shares valued at approximately $98.7 million. Other institutional investors also significantly increased their holdings, leading to institutional ownership of 98.5%. Analyst sentiment is largely positive with a "Moderate Buy" consensus and an average price target of $687, despite recent insider selling by Director Richard S. Levy and insider David Soergel under 10b5-1 plans.
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential
Madrigal Pharmaceuticals (MDGL) is a biotechnology company focused on MASH therapies, with its flagship product, Rezdiffra, positioning it for significant growth. Despite current unprofitability, analysts project a potential upside of 39.49%, driven by strong revenue growth and a robust pipeline. Investors are advised to consider the company's innovation potential against its financial challenges and monitor clinical developments.
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1
This article focuses on the "Return on invested capital %" for Madrigal Pharmaceuticals, Inc. (XETR:YDO1), as presented on TradingView. It provides financial data and indicates the company's market status as closed with no current trades.
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1
This page provides key financial statistics and ratios for Madrigal Pharmaceuticals, Inc. (XETR:YDO1), including market capitalization, P/E Ratio, EPS, and ROI. Users can access annual or quarterly data for various financial years, covering valuation, profitability, liquidity, solvency ratios, and per-share metrics.
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Madrigal Pharmaceuticals (MDGL) is under investor scrutiny after new data on its MASH drug Rezdiffra and subsequent analyst upgrades. Despite recent stock fluctuations, analysts now peg the fair value for MDGL at approximately $671.07, suggesting it is currently undervalued. The article advises investors to weigh potential rewards against risks related to Rezdiffra's market performance and competition.
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Madrigal Pharmaceuticals (MDGL) is under scrutiny after new Rezdiffra data presented at EASL Congress 2026 showed improved liver and cardiovascular risk markers, leading to analyst upgrades. Despite a recent share price pullback and some insider sales, the stock has shown strong long-term momentum. Analysts now have a higher price target of $671.07, indicating it is undervalued, but the valuation depends on Rezdiffra's continued success and limited competition.
